AXSM Axsome Therapeutics, Inc.

NASDAQ

$195.09

Axsome Therapeutics, Inc. (AXSM) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.54 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.6% since its last earnings release on August 10, 2026.

Axsome Therapeutics Reported In-line with Estimates

Monday, August 10, 2026 · 7:00 AM ET

3rd Quarter, Sep 2026

Monday · 7:00 AM ET

Earnings Whisper

-

vs ($0.54)

Rev est $255.7M

Volatility

Enter your expectations below to reveal the current volatility.

Trend Analysis

Expectation

Earnings

Price action

Signals

Score

Sentiment

Grade

Life Cycle

Call Analysis

Earnings-AVWAP $210.46

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Axsome Therapeutics, Inc.

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 8 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.